Blueprint Medicines (BPMC) Projected to Post Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC) is projected to announce its earnings results before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Blueprint Medicines Trading Up 2.0 %

Shares of NASDAQ:BPMC opened at $103.56 on Thursday. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $6.58 billion, a PE ratio of -49.08 and a beta of 0.62. Blueprint Medicines has a 1 year low of $72.24 and a 1 year high of $121.90. The firm has a fifty day moving average price of $99.65 and a 200 day moving average price of $94.77.

Insider Activity

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 15,161 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the sale, the director now directly owns 152,396 shares of the company’s stock, valued at approximately $16,691,933.88. The trade was a 9.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kate Haviland sold 2,353 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $96.60, for a total value of $227,299.80. Following the completion of the transaction, the chief executive officer now directly owns 150,824 shares of the company’s stock, valued at approximately $14,569,598.40. The trade was a 1.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 49,851 shares of company stock worth $4,984,696. Company insiders own 4.21% of the company’s stock.

Analyst Ratings Changes

BPMC has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Monday, January 13th. Wedbush restated an “outperform” rating and issued a $124.00 price objective (down from $135.00) on shares of Blueprint Medicines in a research note on Monday, January 13th. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Finally, UBS Group started coverage on shares of Blueprint Medicines in a report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $123.72.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.